$0.20
(Market cap
$3,870 Mln
Revenue (TTM)
$234 Mln
P/E Ratio
--
P/B Ratio
3.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-7.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.9
-
Face value
--
-
Shares outstanding
96,489,484
7 Years Aggregate
CFO
$-281.87 Mln
EBITDA
$-365.93 Mln
Net Profit
$-332.22 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ideaya Biosciences Inc (IDYA)
| 16.1 | 13.1 | 38.7 | 63.5 | 10.5 | 10.3 | -- |
|
BSE Sensex
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Ideaya Biosciences Inc (IDYA)
| 34.5 | -27.6 | 95.8 | -23.1 | 68.9 | 86.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ideaya Biosciences Inc (IDYA)
|
40.2 | 3,870.2 | 234.1 | -175.0 | -92.7 | -15.8 | -- | 3.4 |
| 82.5 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 70.7 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 57.3 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 108.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 365.7 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 349.9 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 145.0 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Ideaya Biosciences Inc (IDYA)
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein... kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-R Read more
-
President, CEO & Director
Mr. Yujiro S. Hata
-
President, CEO & Director
Mr. Yujiro S. Hata
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ideaya Biosciences Inc (IDYA)
What is the current share price of Ideaya Biosciences Inc (IDYA) Today?
The share price of Ideaya Biosciences Inc (IDYA) is $40.15 (NASDAQ) as of 02-Sep-2026 11:36 EDT. Ideaya Biosciences Inc (IDYA) has given a return of 10.48% in the last 3 years.
What is the current PB & PE ratio of Ideaya Biosciences Inc (IDYA)?
Since, TTM earnings of Ideaya Biosciences Inc (IDYA) is negative, P/E ratio is not available.
The P/B ratio of Ideaya Biosciences Inc (IDYA) is 3.36 times as on 28-Aug-2026, a 35 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-26.93 |
2.99 |
2024 |
-8.18 |
2.12 |
2023 |
-20.55 |
3.74 |
2022 |
-15.96 |
2.50 |
2021 |
-19.15 |
3.02 |
What is the 52 Week High and Low of Ideaya Biosciences Inc (IDYA)?
The 52-week high and low of Ideaya Biosciences Inc (IDYA) are Rs 42.68 and Rs 23.23 as of 02-Sep-2026.
What is the market cap of Ideaya Biosciences Inc (IDYA)?
Ideaya Biosciences Inc (IDYA) has a market capitalisation of $ 3,870 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Ideaya Biosciences Inc (IDYA)?
Before investing in Ideaya Biosciences Inc (IDYA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.